Decoding the role of cancer-associated fibroblasts in cisplatin resistance of head and neck squamous cell carcinoma
Abstract
Cisplatin remains the primary chemotherapy drug for the treatment of head and neck squamous cell carcinoma (HNSCC). However, acquired resistance significantly limits its clinical application, contributing to treatment failure and a poor patient prognosis. Cancer-associated fibroblasts (CAFs) in the tumor microenvironment influence HNSCC sensitivity to cisplatin by modulating tumor cell responsiveness to treatment via paracrine signaling. CAFs impede deep penetration into tumors by remodeling the extracellular matrix (ECM). Various subtypes of cisplatin-resistant CAFs have been identified in HNSCC. Potential compounds targeting these subtypes could enhance cisplatin sensitivity. Simulation of the dynamic tumor microenvironment remains limited in research, hindering clinical translation. Bioinformatics has shifted research into cisplatin resistance in HNSCC. Single-cell sequencing and spatiotemporal transcriptomics could analyze the molecular profiles of CAFs that promote drug resistance in greater depth, potentially facilitating the development of highly targeted drugs and effective combination therapy strategies to overcome cisplatin resistance in HNSCCs.
Related
- Fingolimod overcomes cisplatin resistance in esophageal squamous cell carcinoma by targeting NUP54 to disrupt homologous recombination repair.
- Single-cell spatial transcriptomics identifies SERPINE1 as a vascular endothelial mediator of cisplatin resistance in head and neck squamous cell carcinoma.
- Distal-less homeobox 5 gives rise to myofibroblastic carcinoma-associated fibroblasts to promote collective breast cancer invasion
- Stress-adapted cancer-associated fibroblasts as mediators of immunosuppression and therapy resistance
- Cannabidiol impairs tumor-associated behaviors and modulates apoptosis- and autophagy-related pathways in cisplatin-resistant head and neck squamous cell carcinoma
BibTeX
@article{liu2026decoding,
title = {{Decoding the role of cancer-associated fibroblasts in cisplatin resistance of head and neck squamous cell carcinoma}},
author = {Dongmei Liu and Dilong Yu and Mengyu Chen and Tian Dai and Xingnuo Li and Dan Su and Juyan Zheng and Yiwen Zhang},
journal = {iScience},
year = {2026},
month = sep,
doi = {10.1016/j.isci.2026.117696},
url = {https://www.cell.com/iscience/fulltext/S2589-0042(26)03077-4},
note = {CC BY},
}
RIS
TY - JOUR
TI - Decoding the role of cancer-associated fibroblasts in cisplatin resistance of head and neck squamous cell carcinoma
AU - Dongmei Liu
AU - Dilong Yu
AU - Mengyu Chen
AU - Tian Dai
AU - Xingnuo Li
AU - Dan Su
AU - Juyan Zheng
AU - Yiwen Zhang
PY - 2026
DA - 2026/09/22
JO - iScience
DO - 10.1016/j.isci.2026.117696
UR - https://www.cell.com/iscience/fulltext/S2589-0042(26)03077-4
AB - Cisplatin remains the primary chemotherapy drug for the treatment of head and neck squamous cell carcinoma (HNSCC). However, acquired resistance significantly limits its clinical application, contributing to treatment failure and a poor patient prognosis. Cancer-associated fibroblasts (CAFs) in the tumor microenvironment influence HNSCC sensitivity to cisplatin by modulating tumor cell responsiveness to treatment via paracrine signaling. CAFs impede deep penetration into tumors by remodeling the extracellular matrix (ECM). Various subtypes of cisplatin-resistant CAFs have been identified in HNSCC. Potential compounds targeting these subtypes could enhance cisplatin sensitivity. Simulation of the dynamic tumor microenvironment remains limited in research, hindering clinical translation. Bioinformatics has shifted research into cisplatin resistance in HNSCC. Single-cell sequencing and spatiotemporal transcriptomics could analyze the molecular profiles of CAFs that promote drug resistance in greater depth, potentially facilitating the development of highly targeted drugs and effective combination therapy strategies to overcome cisplatin resistance in HNSCCs.
SN - 2589-0042
ER -